NCT02373046View on ClinicalTrials.gov

Bioequivalence Study Between 400 mg LX4211 Tablets and 2 X 200 mg LX4211 Tablets

PHASE1CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

February 28, 2015

Primary Completion Date

April 30, 2015

Conditions
Healthy
Interventions
DRUG

LX4211

Single dose of LX4211 400 mg as 1 × 400-mg tablet Day 1 or Day 9

DRUG

LX4211

Single dose of LX4211 400 mg as 2 × 200-mg tablets on Day 1 or Day 9

Trial Locations (1)

75247

Lexicon Investigational Site, Dallas

Sponsors
All Listed Sponsors
lead

Lexicon Pharmaceuticals

INDUSTRY